Clinical Trial Update: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of SHR-A2102 in combination with antitumor therapy is being conducted for advanced urothelial carcinoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• SHR-A2102

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Advanced Urothelial Carcinoma | Phase 1, Phase 2 | Status: RECRUITING